Designing neuroprotection trials in Parkinson's disease
Identifieur interne : 001788 ( Main/Exploration ); précédent : 001787; suivant : 001789Designing neuroprotection trials in Parkinson's disease
Auteurs : Karl Kieburtz [États-Unis]Source :
- Annals of Neurology [ 0364-5134 ] ; 2003.
Abstract
A major goal of the neuroscience community is to develop neuroprotective treatment strategies that will slow or forestall the progression of Parkinson's disease, one of the most common adult‐onset neurodegenerative disorders, affecting approximately 1 million people in North America. Although prior research to identify neuroprotective interventions has not been conclusive, recent advances in the understanding of the pathogenesis of Parkinson's disease, including the development of relevant animal models, provide the opportunity for rational clinical trials to assess neuroprotective treatments.Ann Neurol 2003;53 (suppl 3):S100–S109
Url:
DOI: 10.1002/ana.10484
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Designing neuroprotection trials in Parkinson's disease</title><author><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:B0605A4B6C383DCC4D7989E4E6139A4ACEA0F831</idno><date when="2003" year="2003">2003</date><idno type="doi">10.1002/ana.10484</idno><idno type="url">https://api.istex.fr/document/B0605A4B6C383DCC4D7989E4E6139A4ACEA0F831/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002428</idno><idno type="wicri:Area/Main/Curation">002102</idno><idno type="wicri:Area/Main/Exploration">001788</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Designing neuroprotection trials in Parkinson's disease</title><author><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>University of Rochester Medical Center, Rochester</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="sub">Official Journal of the American Neurological Association and the Child Neurology Society</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><date type="published" when="2003">2003</date><biblScope unit="volume">53</biblScope><biblScope unit="issue">S3</biblScope><biblScope unit="supplement">3</biblScope><biblScope unit="page" from="S100">S100</biblScope><biblScope unit="page" to="S109">S109</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">B0605A4B6C383DCC4D7989E4E6139A4ACEA0F831</idno><idno type="DOI">10.1002/ana.10484</idno><idno type="ArticleID">ANA10484</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A major goal of the neuroscience community is to develop neuroprotective treatment strategies that will slow or forestall the progression of Parkinson's disease, one of the most common adult‐onset neurodegenerative disorders, affecting approximately 1 million people in North America. Although prior research to identify neuroprotective interventions has not been conclusive, recent advances in the understanding of the pathogenesis of Parkinson's disease, including the development of relevant animal models, provide the opportunity for rational clinical trials to assess neuroprotective treatments.Ann Neurol 2003;53 (suppl 3):S100–S109</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001788 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001788 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:B0605A4B6C383DCC4D7989E4E6139A4ACEA0F831
|texte= Designing neuroprotection trials in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |